Revance Therapeutics Inc

Revance Therapeutics Inc

  • Price (USD)27.53
  • Today's Change-0.31 / -1.11%
  • Shares traded394.08k
  • 1 Year change-13.83%
  • Beta1.2474
Data delayed at least 15 minutes, as of Sep 20 2021 21:00 BST.
More ▼
Take Survey
Help shape our future virtual events & community services
Take part in our survey for a chance to win a free 3-month standard gift subscription.

Profile data is unavailable for this security.

About the company

Revance Therapeutics, Inc. is a biotechnology company that is focused on aesthetic and therapeutic offerings, including neuromodulator product, DaxibotulinumtoxinA for Injection. The DaxibotulinumtoxinA for Injection combines a proprietary stabilizing peptide excipient with purified botulinum toxin that does not contain human or animal-based components. The Company is also evaluating DaxibotulinumtoxinA for Injection in the full upper face, including glabellar lines, forehead lines, and crow’s feet, as well as in two therapeutic indications cervical dystonia and adult upper limb spasticity. It offers products and services for United States aesthetics practices, including the resilient hyaluronic acid (RHA) Collection of dermal fillers and HintMD fintech platform. The RHA Collection of dermal fillers is a filler for the correction of dynamic facial wrinkles and folds. HintMD fintech platform includes integrated smart payment, subscription, and loyalty digital services.

  • Revenue in USD (TTM)47.07m
  • Net income in USD-303.40m
  • Incorporated1999
  • Employees470.00
  • Location
    Revance Therapeutics Inc1222 Demonbreun Street, Suite 2000NASHVILLE 37203United StatesUSA
  • Phone+1 (615) 724-7755
  • Fax+1 (302) 674-5266
  • Websitehttp://www.revance.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Rubius Therapeutics Inc0.00-173.90m1.88bn231.00--7.10-----2.08-
Deciphera Pharmaceuticals Inc83.66m-258.17m1.91bn350.00--4.29--22.88-4.50-4.501.467.700.13640.35736.44239,040.00-42.09-41.47-46.54-45.5797.95---308.58-946.276.49--0.00--68.35---38.61--106.38--
Regenxbio Inc161.28m-145.23m1.92bn306.00--3.78--11.90-3.56-3.564.0211.920.2508--3.70527,045.80-22.58-12.90-25.16-13.8073.7886.71-90.05-57.21---38.670.00--338.7082.72-17.44--119.95--
Cassava Sciences Inc0.00-12.70m1.94bn11.00--7.02-----0.3658-0.36580.006.910.00----0.00-8.28-32.35-8.44-33.81------------0.00-------36.77------
Castle Biosciences Inc78.09m-22.55m1.95bn199.00--4.68--24.92-0.9869-0.98693.4416.530.24516.265.15392,397.00-7.08---7.64--84.80---28.88--20.88-19.330.00--20.79---443.83------
Jufeel International Group19.35m6.62m1.95bn144.00----260.34100.760.23620.23620.69041.170.40341.7724.22134,392.9014.07--22.24--77.98--34.87--0.114--0.0249---36.72---56.36------
Revance Therapeutics Inc47.07m-303.40m2.00bn470.00--10.73--42.48-4.72-4.720.72992.590.07744.93136.44100,151.10-49.86-50.74-54.63-56.1269.43---644.56-3,963.976.00-29.900.6006--3,610.65119.61-76.94--4.84--
Ironwood Pharmaceuticals, Inc.413.02m508.86m2.01bn232.003.963.933.934.873.123.122.553.140.5694--3.981,780,276.0070.15-6.2878.91-7.3199.7895.35123.20-9.54--6.810.4634---9.0821.1080.13---14.57--
Xencor Inc178.63m23.52m2.02bn202.0094.423.1267.4611.290.36610.36613.0611.090.2666--14.73884,316.803.51-3.443.83-4.05----13.17-18.23----0.00---21.7034.61-357.98--30.23--
Amarin Corporation plc (ADR)620.41m4.32m2.03bn1.00k490.483.15306.283.280.01050.01051.571.630.63310.6464.04620,408.000.4409-14.030.6616-21.6679.3277.190.6963-19.181.95--0.00--42.8949.6720.51--55.18--
Harmony Biosciences Holdings Inc235.39m17.19m2.10bn150.00126.5416.5763.658.910.29070.29074.072.220.890811.6310.141,569,280.008.78--9.86--82.62--9.86--5.461.910.6072--2,564.59--65.89------
Myovant Sciences Ltd67.05m-283.93m2.10bn407.00------31.35-3.13-3.130.7399-4.350.1569----164,734.60-66.46-110.31-114.88-176.3385.63---423.49-1,758.892.27-24.64--------11.71------
Organogenesis Holdings Inc433.35m70.06m2.14bn910.0029.6011.9427.234.940.56280.56283.421.391.523.677.18476,213.2024.49-7.7533.25-9.0476.02--16.17-11.312.057.700.3181--29.63--143.67------
Atea Pharmaceuticals Inc175.01m35.29m2.17bn49.0066.493.6361.4912.410.39450.39452.067.220.3531----4,487,411.007.12--9.93------20.16------0.00------22.00------
Rocket Pharmaceuticals Inc0.00-164.70m2.18bn91.00--4.43-----2.81-2.810.007.710.00----0.00-37.09-28.32-39.12-30.01-----------46.740.0501-------80.79--134.25--
ADC Therapeutics SA3.76m-200.35m2.21bn208.00--9.08--588.88-2.61-2.610.0493.180.009----18,076.92-47.80---53.05--96.78---5,328.54--7.51--0.2896---100.00---111.44------
Data as of Sep 20 2021. Currency figures normalised to Revance Therapeutics Inc's reporting currency: US Dollar USD

Institutional shareholders

45.83%Per cent of shares held by top holders
HolderShares% Held
BlackRock Fund Advisorsas of 30 Jun 20214.69m6.52%
GIC Pte Ltd. (Investment Management)as of 31 Dec 20203.83m5.33%
The Vanguard Group, Inc.as of 30 Jun 20213.42m4.76%
JPMorgan Investment Management, Inc.as of 30 Jun 20213.38m4.71%
Palo Alto Investors LPas of 30 Jun 20213.20m4.46%
AllianceBernstein LPas of 30 Jun 20213.09m4.30%
Capital Research & Management Co. (World Investors)as of 30 Jun 20212.97m4.13%
ArrowMark Colorado Holdings LLCas of 30 Jun 20212.88m4.01%
Wellington Management Co. LLPas of 30 Jun 20212.77m3.86%
Fidelity Management & Research Co. LLCas of 30 Jun 20212.70m3.75%
More ▼
Data from 30 Jun 2021 - 14 Sep 2021Source: FactSet Research Systems Inc.
Refinitiv, an LSEG business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.